Pembrolizumab has emerged as the standard of care for stage IV, non-oncogene-addicted advanced non-small cell lung cancer (aNSCLC) patients with programmed death-ligand 1 (PD-L1) expression ≥ 50% [1]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.